Glenmark Pharms. Inc.

Glenmark Pharms. Inc. is the U.S. subsidiary of Glenmark Pharmaceuticals Ltd., a global, research-led pharmaceutical company headquartered in Mumbai, India. Glenmark Pharmaceuticals Ltd. was founded in 1977 and is publicly traded on the NSE and BSE. The U.S. subsidiary, Glenmark Pharmaceuticals Inc., USA, was established in 2003 and has its corporate office in Elmwood Park, New Jersey, with manufacturing operations in Monroe, North Carolina, and a distribution center in Allentown, Pennsylvania. The parent company employs over 10,000 people globally, with annual revenues estimated between $1.5 billion and $3.3 billion.

The company specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including generics, specialty pharmaceuticals, and over-the-counter (OTC) medications. Glenmark focuses on key therapeutic areas such as Dermatology, Respiratory, and Oncology, and has a robust pipeline of new drugs. Their product portfolio includes generic versions of various medications and branded products like Ryaltris, an FDA-approved nasal spray for allergic rhinitis, and Telma for hypertension.

Glenmark Pharms. Inc. currently has one tracked patent litigation case, in which it appears as a defendant. This posture indicates that the company operates as an operating entity that defends against patent infringement claims, rather than primarily asserting patents as a non-practicing entity (NPE).

The single tracked case, Veloxis Pharmaceuticals, Inc. v. Glenmark Pharms. Inc., was filed in the District Court, Delaware, on April 14, 2025. This case aligns with the typical litigation landscape for pharmaceutical companies, which often involve challenges related to drug patents.